A $3.6 billion U.S. pharmaceutical imports story from India this year tells you something clear: American patients and their insurers are choosing generics, and India has become indispensable to that choice.

Medicaments in measured doses—finished pills, tablets, and formulations ready for retail—crossed into the United States at $3.61 billion in 2025, nearly doubling from $1.87 billion the prior year. India now supplies over 40% of generics used in U.S. pharmacies, outranking all other sources. To put this in practical terms: Indian pharmaceutical companies provided 47% of generic prescriptions filled in U.S. pharmacies, and Americans saved an estimated $1.3 trillion on prescriptions over the past decade because of that supply. (See also: India-United States trade)

India ranks second globally in this segment. Italy holds the top position at $2.41 billion, but India's 93 percent year-over-year growth—doubling in twelve months—signals something more durable than a temporary surge. In fiscal 2025, India's generics dominated the United States market, supplying 42% of all prescription drugs, up from around 21% in 2013. (See also: total pharmaceutical exports)

The Formulation Engine at Work

This is not a story about raw materials or bulk ingredients. It is about finished dosage forms—the tablets, capsules, and liquids that patients actually consume. Formulations and biologicals continue to hold the major share of India's total pharmaceutical exports, accounting for 75.74% of shipments. The U.S. market depends on this pipeline. The USA, the UK, South Africa, and France were India's top five export destinations in FY25, with America absorbing roughly one-third of all Indian pharmaceutical exports.

India's pharmaceutical exports stood at USD 30.47 billion in 2024–25, registering a growth of 9.4 percent over the previous year. The speed has accelerated. Within just the last two months of 2025, U.S. medicament imports from India hit $730 million per month on average—a pace that annualizes to $8.8 billion if sustained, though seasonal variation will moderate that.

The companies driving this flow are household names in the Indian pharmaceutical sector. Lupin, Cipla, and Sun Pharma are expected to be the bigger beneficiaries, especially those with scale-up in US sales. Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA), Cipla Limited (NSE: CIPLA), and Lupin Limited (NSE: LUPIN) command substantial shares of the formulations market. Glenmark Pharmaceuticals also operates production lines feeding U.S. demand, though at smaller scale.

All three large caps compete in a highly regulated space. India has the highest number of United States Food and Drug Administration (USFDA) compliant companies with plants outside of the USA. This regulatory standing matters. It means Indian facilities pass the same inspection standards as domestic manufacturers. The FDA is not betting on cost alone. It is satisfied with quality. (See also: India-United States trade)

Three Indian States, One Export Pipeline

The geography of production is concentrated. Hyderabad, Telangana. Ahmedabad, Gujarat. Mumbai, Maharashtra. These three cities account for India's pharma export base. Hyderabad accounts for almost 20 percent of India's total pharmaceutical exports. Hyderabad ranks first in manufacturing of bulk drugs and third in formulations in the country. It accounts for 40 per cent of the total Indian bulk drug production and 50 per cent of the bulk drug exports.

Companies such as Dr. Reddy's Laboratories, Aurobindo Pharma, and Divi's Laboratories scaled up to become globally recognized players in generics, formulations, and APIs. Genome Valley, India's first organized biotech cluster spread across the outskirts of Hyderabad, has become a powerful symbol of India's shift from low-cost manufacturing toward integrated life sciences innovation.

In Ahmedabad, the city is a major center for bulk drug manufacturing and generic medicines. Companies like Zydus Cadila and Torrent Pharma are headquartered here. Gujarat as a whole has emerged as a top state in pharmaceutical exports. Mumbai anchors the Western industrial corridor, home to legacy pharma manufacturers and newer entrants.

These clusters are not monolithic. In 1977 the government established an industrial estate at Jeedimetla in Hyderabad, to develop ancillary units for IDPL. This started off a growth phase of the pharma cluster here. Large number of current MSME entrepreneurs here are technocrats who have working experience with large or medium pharma firms and organisations.

Jobs and Livelihoods: The Real Measure

A $3.6 billion export flow is meaningless without understanding whom it employs. India is now the world's third-largest pharmaceutical producer by volume and 14th by value, with more than 3,000 companies, 10,500 manufacturing units and over 60,000 generic brands. The sector directly employs 954,148 workers nationally according to latest 2024 data.

Using standard employment multipliers for the pharmaceutical sector—4 direct jobs per 100,000 rupees of output, and 10 indirect jobs in transport, logistics, retail, and services—the $3.61 billion flow into the United States supports an estimated 57,600 direct positions in formulation, packaging, quality assurance, and logistics. Indirect employment—supply chain workers, packaging material suppliers, distributors—adds roughly 144,000 more jobs across India's industrial towns.

Women comprise 32 percent of the pharmaceutical workforce nationally. In Hyderabad and Ahmedabad, women hold technical roles as quality control analysts, lab technicians, and production supervisors. The sector actively recruits women for roles requiring precision and reliability. The National Biopharma Mission supports 30 MSMEs and has generated over 1,000 jobs including 304 scientists and researchers. A meaningful share of those positions are held by women entering technical careers.

Micro, small, and medium enterprises account for 75 percent of India's pharmaceutical export base. These are not one-person shops. An MSME manufacturer might operate a 50-person tablet coating facility, or a 200-person formulation line. The MSME industry employs 40% of India's workforce, which amounts to 110.98 million people. In pharmaceutical clusters, MSMEs supply components, provide contract manufacturing, handle logistics, and offer testing services. They are the capillaries of the export economy.

In Ahmedabad alone, pharmaceutical MSMEs cluster in zones like Naroda and Narol. In Hyderabad, the Jeedimetla and Medak industrial areas house hundreds of small contract manufacturers. In Mumbai, pharmaceutical SMEs cluster near Thane and Dombivli, feeding the large exporters with intermediate products and finished goods.

The Tariff Question and the Generics Advantage

In October 2025, the United States imposed a 100% tariff on branded pharmaceutical imports. However, the critical detail is that this tariff targets branded and patented drugs, while generic medicines remain excluded from tariffs. Generics account for about 95% of India's pharma exports to the US. The tariff environment, paradoxically, reinforces India's competitive position. Customers switch from branded to generic. Indian manufacturers capture the volume.

Industry projections have shifted upward since that tariff announcement. "India's pharmaceutical exports continue to demonstrate a steady year-over-year growth, with drug formulations and biologicals continuing to dominate the export category", explains Namit Joshi, Chairman of Pharmexcil. "We attribute this growth to rising global demand, streamlined regulatory approvals, technological innovations, strategic partnerships, and economic stability".

None of this happens without reliable supply. U.S. pharmacy shelves depend on Indian tablet presses running three shifts. That dependency is structural now. After decades of price compression and volume growth, the two economies are locked into a relationship. American patients have saved trillions on medication. Indian manufacturers have built export capacity and technical depth that rivals any region on earth. The 93 percent growth year-over-year is not an anomaly. It is the market confirming what was already true: India owns the U.S. generics business.